Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche parathyroid hormone osteoporosis research has Phase II candidate; NDA pending for Tasmar.

Executive Summary

ROCHE PARATHYROID HORMONE OSTEOPOROSIS RESEARCH HAS CANDIDATE IN PHASE II, the company indicated. A Roche-developed parathyroid hormone related peptide (RS-66271) was found in preclinical models to be more effective than parathyroid hormone in restoring bone mass density, Roche Bioscience Osteoporosis & Endocrine Research Director Brian Vickery, PhD, told a Cambridge Healthtech Institute meeting in Philadelphia Oct. 15 on osteoporosis therapies.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts